Novo Nordisk is set to showcase its newest weight-loss treatment during the Super Bowl 2026, rolling out a high-profile commercial to promote the pill form of its blockbuster obesity drug Wegovy.
The oral version of Wegovy, the first of its kind, became available in January 2026, expanding treatment options beyond the injectable form that helped propel the drug to global prominence. The company’s decision to debut the pill on the Super Bowl stage highlights its ambition to reach a broader audience as demand for weight-loss medications continues to soar.
The Big Game advertisement features a star-studded cast that includes Kenan Thompson, DJ Khaled, Danielle Brooks, Ana Gasteyer, John C. Reilly and Danny Trejo, blending humor and star power to draw attention to the newly launched pill.
In a statement released ahead of the commercial’s airing, DJ Khaled spoke candidly about his own health and fitness journey, noting that consistent exercise and disciplined eating do not always deliver the desired results. He said that reality made the message behind Wegovy’s pill option especially meaningful to him.
Khaled also emphasized the personal motivation behind his partnership with Novo Nordisk, pointing to his role as a father and husband. He said his goal is to be at his best for his family and described the availability of a pill-based option as a powerful tool for people striving to reach their weight-loss goals.
Novo Nordisk’s Super Bowl push comes as competition in the obesity drug market intensifies, with pharmaceutical companies racing to develop more convenient and accessible treatments. By pairing a new pill formulation with one of the world’s most-watched advertising events, the company aims to cement Wegovy’s position at the forefront of the rapidly expanding weight-loss market.
